Entries Invited for 1997 Rose Kushner Writing Awards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

BETHESDA, Md--The American Medical Writers Association is accepting applications for the 1997 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer. A cash award of $1,000 for the winning entry in each of five categories will be provided through a grant from Zeneca Pharmaceuticals.

BETHESDA, Md--The American Medical Writers Association is acceptingapplications for the 1997 Rose Kushner Awards for Writing Achievement inthe Field of Breast Cancer. A cash award of $1,000 for the winning entryin each of five categories will be provided through a grant from ZenecaPharmaceuticals.

The awards were established in 1990 as a memorial tribute to Rose R.Kushner, a former member of the Association and a pioneer in breast cancereducation and patient advocacy. A survivor of breast cancer for 16 years,Rose Kushner died on January 7, 1990, at the age of 60.

Award categories include published lay articles (newspapers or magazines),published scientific articles (journals), brochures and monographs, books(medical and lay audiences), and scripts for video, film, or radio (medicaland lay audi-ences). Entries must have been published or shown from March1996 through March 1997.

The competition is open to AMWA and non-AMWA members. Entries may besubmitted by persons other than the writer, but the award, presented atthe AMWA Annual Conference, goes only to the writer.

The deadline for entries is May 10, 1997. For more information, contactthe American Medical Writers Association, 9650 Rockville Pike, Bethesda,MD 20814-3998. Telephone: 301-493-0003; Fax: 301-493-6384.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content